INVO Fertility (NASDAQ:IVF) Issues Earnings Results

INVO Fertility (NASDAQ:IVF) announced its earnings results on Friday. The company reported $0.35 earnings per share (EPS) for the quarter, Zacks reports. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%.

INVO Fertility Price Performance

NASDAQ:IVF traded up $0.00 during trading hours on Friday, hitting $0.97. The company’s stock had a trading volume of 48,505 shares, compared to its average volume of 78,813. INVO Fertility has a 52-week low of $0.90 and a 52-week high of $84.40. The business’s 50-day moving average is $1.28 and its two-hundred day moving average is $2.63. The company has a current ratio of 0.90, a quick ratio of 0.87 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On INVO Fertility

An institutional investor recently bought a new stake in INVO Fertility stock. Armistice Capital LLC bought a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned about 8.69% of INVO Fertility as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.